The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2024 | Current barriers to early intervention in myelofibrosis
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, KS, outlines some barriers to early intervention in patients with myelofibrosis (MF). The development of prognostic tools is needed to accurately predict which patients presenting with early MF are at risk of rapidly progressive disease and would benefit from early intervention. It is also not yet clear which of the agents approved in advanced MF will be appropriate to use in patients with early disease, and Dr Yacoub expresses his excitement at studies that are being designed to investigate this. This interview took place at the 1st Annual MPN Workshop of the Carolinas in Asheville, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Novartis, CTI Pharma, Incyte, Pfizer, Acceleron Pharma, Pharmaessentia.
